A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Recruiting · NCT07175285
Conditions: Systemic Lupus Erythematosus (SLE)
At a glance
- Research payments reported, 2025
- $1,169
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 223
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Current standard of care treatment options (drug)
- Dates
- Started 2025-10-08; completion 2032-10-05
- Results posted
- Not yet
The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants
From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $1,169 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rheumatology Center of San Diego, PC $1,169
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.